Clopidogrel Tablet, Film Coated
Product Images NDC 68071-4023

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 68071-4023). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 4023 3

Label for Clopidogrel 75 mg film-coated tablets from NuCare Pharmaceuticals, Inc. The package contains #30 tablets. Each tablet contains 97.875 mg of Clopidogrel Bisulfate USP equivalent to 75 mg of Clopidogrel base. The label includes manufacturer and lot details, barcode, storage instructions at controlled temperature 68-77°F, and a warning to keep out of reach of children.*

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A horizontal bar chart illustrating the effect of four proton pump inhibitors (Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, Omeprazole 80 mg) on the active metabolite area under the curve (AUC) of Clopidogrel Bisulfate 75 mg. The x-axis shows change relative to clopidogrel bisulfate administered alone, ranging from 0.4 to 1.4. Confidence intervals are displayed for each bar.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

A line graph depicting cumulative event rates (%) for cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up, comparing Clopidogrel Bisulfate plus aspirin versus placebo plus aspirin. The graph shows lower event rates for Clopidogrel Bisulfate with a P-value of 0.00009, indicating statistical significance.*

FDA Label Image

Figure 3: Hazard Ratio For Patient Baseline Characteristics And On-study Concomitant Medications/interventions For The Cure Study (Clopidogrel Fig3)

A forest plot chart showing subgroup analyses of hazard ratios comparing Clopidogrel Bisulfate versus placebo across various patient characteristics such as age, gender, race, diabetes, prior myocardial infarction, stroke, and concomitant medications. The chart displays hazard ratios with 95% confidence intervals for each subgroup, visually indicating whether outcomes favor Clopidogrel or placebo.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

A Kaplan-Meier curve chart comparing the percentage of deaths before first discharge over days since randomization (up to 28 days) between patients treated with Clopidogrel and those given a placebo. The chart shows Clopidogrel associated with a 7% proportional reduction in risk compared to placebo, with death counts and percentages labeled for each group.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

A Kaplan-Meier plot depicting the percentage of patients with death, re-infarction, or stroke events before first discharge over 28 days post-randomization. It compares Clopidogrel (75 mg) to placebo, showing cumulative event rates with a 9% proportional risk reduction for Clopidogrel (9.2%) versus placebo (10.1%).*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

A chart presenting odds ratios with 99% confidence intervals comparing the effectiveness of Clopidogrel Bisulfate versus placebo across various subgroups, including gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent administration. The data include sample sizes and percentages for each subgroup.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

A line graph showing cumulative event rate (%) of fatal or non-fatal vascular events over 36 months of follow-up for aspirin and clopidogrel bisulfate. The graph compares the two treatments, with data points indicating a statistically significant difference (P=0.045).*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

A hazard ratio forest plot comparing the effects of Clopidogrel Bisulfate and Aspirin in different qualifying conditions: stroke, myocardial infarction (MI), and peripheral artery disease (PAD). The plot shows hazard ratios with 95% confidence intervals for each condition and overall, indicating which treatment favors Clopidogrel Bisulfate or Aspirin based on the positions of the markers relative to the vertical line at 1.0.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure of Clopidogrel Bisulfate showing its molecular arrangement with chlorine and sulfur atoms, as well as a sulfate group (H2SO4) indicated in the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.